Abstract
Therapeutic response in patients with advanced breast cancer is conventionally assessed with reference to criteria devised by the International Union Against Cancer. Evidence to date suggests, however, that assessments of equivalent quality may be obtained at lower cost from the use of serum markers. The paper presents estimates of potential cost savings resulting from the use of serum markers in place of conventional assessment and argues that the size of these savings merits the establishment of a randomised controlled trial.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Robertson, J., Whynes, D., Dixon, A. et al. Potential for cost economies in guiding therapy in patients with metastatic breast cancer. Br J Cancer 72, 174–177 (1995). https://doi.org/10.1038/bjc.1995.297
Issue Date:
DOI: https://doi.org/10.1038/bjc.1995.297
This article is cited by
-
Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis
British Journal of Cancer (2007)
-
Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: A prospective study
Breast Cancer (2004)
-
Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: A large-scale retrospective study
Breast Cancer (2003)